Bisphosphonate Effective in Treating Osteonecrosis Pain in Pediatric ALL
Use of the bisphosphonate pamidronate (Aredia) may be “more efficient” than standard regimens as palliative treatment for symptoms of acute symptomatic osteonecrosis in pediatric patients with acute lymphoblastic leukemia. (Source: Cancer Network)
Source: Cancer Network - June 24, 2013 Category: Cancer & Oncology Source Type: news

Cancer Groups Call for Clarity on Patient Access to Clinical Trials
A group of cancer and other healthcare advocacy organizations applauded a provision in the Affordable Care Act that requires private insurers to cover the routine medical costs of patients participating in clinical trials. However, many of those patients will continue to face roadblocks to participating in trials unless the federal government provides clear guidance on implementation, the groups said in a recent letter. (Source: Cancer Network)
Source: Cancer Network - June 24, 2013 Category: Cancer & Oncology Source Type: news

Ibrutinib Shows High Response Rate in Mantle-Cell Lymphoma
Phase II trial results of the targeted agent ibrutinib in relapsed or refractory mantle-cell lymphoma show that the drug led to promising and durable responses. (Source: Cancer Network)
Source: Cancer Network - June 22, 2013 Category: Cancer & Oncology Source Type: news

Patient With Mass in Sacrococcygeal Region
A 58-year-old man presents with pain in the lower back. Radiographic imaging shows a mass in the sacrococcygeal region. Resection of the tumor was performed. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - June 21, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Daratumumab Safe in Multiple Myeloma
Results from a first-in-human trial of daratumumab indicate that the investigational drug reduced paraprotein and bone marrow plasma cells at doses greater than 4 mg/kg in patients with advanced multiple myeloma. (Source: Cancer Network)
Source: Cancer Network - June 21, 2013 Category: Cancer & Oncology Source Type: news

How Honest Is the EMR?
Have you ever read someone’s note in the EMR and noticed it says “normal” in every section under physical exam, when in fact, the patient has had a mastectomy, a markedly enlarged liver, 3+ edema, or (horrors!) an amputation that goes undocumented? (Source: Cancer Network)
Source: Cancer Network - June 21, 2013 Category: Cancer & Oncology Source Type: news

BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer
The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine leads to a significant improvement in progression-free survival compared with placebo in advanced and metastatic HER2-positive breast cancer. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Gene Variations May Predict Response to Breast Cancer Prevention Therapies
Researchers from the Mayo Clinic have identified variants in two genes that result in a higher chance that tamoxifen or raloxifene will actually prevent breast cancer. More studies are needed, but if confirmed, women with these variants may be more likely to undergo the 5-year preventive regimen. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Study: BPA Exposure in Developing Prostate Increases Later Cancer Risk
In a new study presented at the Endocrine Society’s annual meeting, researchers using animal models show that early BPA exposure increases prostate cancer risk. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Denosumab Approved by FDA for Giant-Cell Tumor of the Bone
The first treatment for a rare tumor called giant-cell tumor of the bone has been approved by FDA. The approval of denosumab (Xgeva) was based on a priority FDA review. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
A high baseline level of soluble human epidermal growth factor receptor 2 (sHER2) was a prognostic indicator of shorter disease-free survival among patients with early-stage HER2-positive breast cancer, according to results from the North Central Cancer Treatment Group adjuvant trial N9831. (Source: Cancer Network)
Source: Cancer Network - June 19, 2013 Category: Cancer & Oncology Source Type: news

RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
The mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when given as first-line treatment in patients with metastatic renal cell carcinoma. (Source: Cancer Network)
Source: Cancer Network - June 19, 2013 Category: Cancer & Oncology Source Type: news

ASCO: PD-L1 Antibody Elicits Durable Response in RCC
Researchers observed durable responses in patients with renal cell carcinoma treated with the PD-L1 antibody MPDL3280A. The study, which was presented at the 2013 ASCO Annual Meeting, was one of the few immune therapy trials that allowed patients with non-clear cell histologies and some clinical activity was observed in these patients. (Source: Cancer Network)
Source: Cancer Network - June 19, 2013 Category: Cancer & Oncology Source Type: news

The Emerging Role of HE4 in the Evaluation of Epithelial Ovarian and Endometrial Carcinomas
In this review, we discuss the discovery and biologic significance of HE4 and evaluate available evidence regarding the utility of HE4 as a biomarker for ovarian and endometrial cancer. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

The Key to Improving Survival in Ovarian Cancer: Better Screening of Women With Vague Symptoms, Leading to Earlier Diagnosis, More Effective Surgery
Although the combination of CA-125 and HE4 appears indicated for use in symptomatic patients or in patients with an adnexal mass, there is no evidence that it would be indicated as a screening test in asymptomatic patients. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

Tailored Therapy in Diffuse Gliomas: Using Molecular Classifiers to Optimize Clinical Management
We review the current data regarding the prognostic and predictive value of IDH mutation and 1p/19q codeletion in gliomas. We also discuss possible management algorithms using these biomarkers to tailor surgical and adjuvant therapy for specific diffuse gliomas. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

The Role of Physical Activity in Cancer Prevention, Treatment, Recovery, and Survivorship
This article will review these intersections of exercise and oncology, discuss the known mechanisms by which exercise exerts its salutary effects, and touch upon the future directions of exercise research in the oncology setting. Finally, recommendations are provided for clinicians to help patients with and without cancer take advantage of the benefits of physical activity. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
The use of a yoga program helped to reduce symptoms of insomnia among women with breast cancer undergoing hormonal therapy, and also resulted in an improved quality of life, according to new data presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

Preventing Burnout in Oncology
Developing an effective personal and professional self-care plan can help oncologists deal with the pressures of caring for terminally ill patients and potentially prevent burnout, a recent study suggests. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
Interim results of a small phase II study found a relatively good response rate with dabrafenib in BRAF V600E mutation-positive stage IV non-small-cell lung cancer (NSCLC) patients. The results were presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 18, 2013 Category: Cancer & Oncology Source Type: news

Metaplastic Mammary Carcinoma With Discrepant Hormone Receptor Results by IHC and RT-PCR
The Case: A 48-year-old perimenopausal woman noted a lump in her left breast. She had had a mammogram 9 months earlier without abnormality. After ultrasound imaging confirmed a solitary mass measuring about 1.5 cm, a core needle biopsy demonstrated a poorly differentiated mammary carcinoma with chondroid features. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Fertility Preservation and Breast Cancer: A Complex Problem
A considerable number of women with breast cancer are diagnosed during their reproductive years. In the short period of time in which newly diagnosed women will need to make decisions about surgical options and adjuvant therapy, younger women with breast cancer also face the potential impairment or complete loss of their fertility. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
The goals of care for patients with hormone receptor (HR)-positive advanced breast cancer include prolongation of disease-free and overall survival, amelioration of symptoms, and improvement in quality of life. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Post-Surgery Surveillance Found Safe in Seminoma
Surveillance of patients with stage I seminoma following orchiectomy can spare a majority of patients from adjuvant chemotherapy with a low risk of relapse, according to results presented at the 2013 ASCO meeting. (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Bladder Cancer Recurrence High, Better Follow-Up Care Needed
Recent studies suggest patients with bladder cancer are not receiving optimal care or the follow-up surveillance as recommended by the National Comprehensive Cancer Network (NCCN). (Source: Cancer Network)
Source: Cancer Network - June 17, 2013 Category: Cancer & Oncology Source Type: news

Intermittent Imatinib for Elderly CML Patients Shows Promise
A phase II study found that an alternative imatinib treatment schedule for elderly patients with chronic myeloid leukemia (CML) could be an effective way to reduce dosing requirements of the drug. (Source: Cancer Network)
Source: Cancer Network - June 15, 2013 Category: Cancer & Oncology Source Type: news

When Do You Recommend Molecular Profiling of Tumors?
How often do you refer patients for molecular profiling of a malignant tumor? For which of the following tumor types would you be most likely to recommend molecular profiling? Answer these questions and more. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news

Supreme Court Ruling Invalidates Myriad’s BRCA Gene Patents
The Supreme Court announced a unanimous 9-0 decision that genes cannot be patented. After a long legal battle, the high court ruled against Myriad’s patents on two breast cancer susceptibility genes—BRCA1 and BRCA2—declaring that genes are products of nature and cannot be treated as inventions. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Cetuximab Ups Survival Over Bevacizumab in Colorectal Cancer
Results from the German AIO KRK-0306 study, FIRE-3, show that the addition of cetuximab (Erbitux) to chemotherapy rather than bevacizumab (Avastin) increased overall survival by nearly 4 months in patients with KRAS wild-type metastatic colorectal cancer. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news

Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse
Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib treatment did not relapse, according to results of a prospective study. Those who did relapse showed continued sensitivity to imatinib when treatment started again. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news

Vegetable Fats May Reduce Risk of Death in Prostate Cancer Patients
A new study shows that men diagnosed with prostate cancer may do better by substituting carbohydrates and saturated fats with plant-based fats such as those found in nuts and olive oil. (Source: Cancer Network)
Source: Cancer Network - June 14, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Sunitinib Improves PFS in Small-Cell Lung Cancer
A randomized, phase II trial showed improved progression-free survival in small-cell lung cancer with maintenance sunitinib vs placebo following standard chemotherapy, according to results presented at the ASCO annual meeting in Chicago. (Source: Cancer Network)
Source: Cancer Network - June 12, 2013 Category: Cancer & Oncology Source Type: news

Active Surveillance Not Only Reduces Morbidity, It Saves Lives
The concept of active surveillance is based on the observation that Gleason 6 (pattern 3) prostate cancer is an indolent condition that poses little or no threat to the patient’s life. Conservative management is thus appropriate for these patients. (Source: Cancer Network)
Source: Cancer Network - June 11, 2013 Category: Cancer & Oncology Source Type: news

Surveillance for Prostate Cancer: Are the Proceduralists Running Amok?
In my experience, being treated for low-volume Gleason 6 tumors is the norm, not the exception, for men in the United States. Surveillance may be discussed as an option, but it is not taken seriously. (Source: Cancer Network)
Source: Cancer Network - June 11, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Treating Lung Cancer After Targeted Therapy–Resistance
Today at the 2013 ASCO meeting, we are discussing targeted therapy strategies for lung cancer and for treating patients after resistance to these drugs. (Source: Cancer Network)
Source: Cancer Network - June 11, 2013 Category: Cancer & Oncology Source Type: news

Pain or Feign?
In the late 1960s, I quickly learned that a large proportion of requests for narcotics in this population were spurious. Patients would simulate renal stone, acute myocardial infarction, and many other painful illnesses in order to obtain narcotic drugs. (Source: Cancer Network)
Source: Cancer Network - June 10, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Sorafenib Slows Progression in Advanced Thyroid Cancer
Data presented at ASCO from the phase III DECISION trial showed treatment with the TKI sorafenib (Nexavar) delayed disease progression by 5 months in patients with metastatic differentiated thyroid cancer that had progressed on radioactive iodine. (Source: Cancer Network)
Source: Cancer Network - June 10, 2013 Category: Cancer & Oncology Source Type: news

ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Results of two phase III trials, presented at ASCO, on the addition of bevacizumab (Avastin) to standard therapy in newly diagnosed glioblastoma found that the drug added no benefit. (Source: Cancer Network)
Source: Cancer Network - June 10, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Dr. Martine Piccart, in Karnofsky Lecture, Outlines Vision for the Empowering of Academic Research
The David A. Karnofsky Memorial Award, ASCO’s highest scientific honor, went this year to Dr. Martine J. Piccart, who is internationally recognized for her unflagging dedication and innovative approaches to the development of drugs and regimens that will truly make a difference in the lives of patients with breast cancer. (Source: Cancer Network)
Source: Cancer Network - June 10, 2013 Category: Cancer & Oncology Source Type: news

A 48-Year-Old Woman With Irregular Vaginal Bleeding
A 48-year-old female presents with complaints of irregular vaginal bleeding and postcoital bleeding. Images from a PET/CT and pelvis MRI reveal characteristic findings. What is your diagnosis? (Source: Cancer Network)
Source: Cancer Network - June 10, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Avastin Improves Survival in Advanced Cervical Cancer
Results from the phase III GOG 240 trial, presented at ASCO, showed the addition of bevacizumab (Avastin) to standard chemotherapy improved overall survival by nearly 4 months in women with advanced or relapsed cervical cancer. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
Biennial visual inspection with acetic acid (vinegar) screening by trained public health workers significantly reduced cervical cancer mortality in a large cluster-randomized controlled trial conducted among thousands of women from poor neighborhoods in Mumbai, India. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy by Subtype
In a study presented at ASCO, a team of researchers used microarrays to characterize 130 triple-negative breast cancer patients treated with neoadjuvant chemotherapy to see whether certain subtypes are more likely to respond to the treatment. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Frequent Genetic Mutations in Black Women With Breast Cancer
A single-center study analyzed the frequency of breast cancer susceptibility mutations among black women diagnosed with breast cancer. The findings suggest that broader genetic screening may be beneficial for these women. The study also suggests that family history is not the only criteria by which patients at risk for breast cancer can be identified. (Source: Cancer Network)
Source: Cancer Network - June 7, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Updated Analyses Confirm Safety and Efficacy of Ra-223 in CRPC
Further analyses of data subsets from the ALSYMPCA study of the alpha particle-emitting isotope Ra-223 (Xofigo) were presented at ASCO, providing additional evidence of efficacy and safety of the recently FDA approved therapeutic agent. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Pemetrexed Plus Carboplatin No Better Than Bevacizumab-Containing Regimen in NSCLC
A phase III study, presented at ASCO, comparing pemetrexed and carboplatin with paclitaxel, carboplatin, and bevacizumab failed to find a difference in a composite endpoint of progression-free survival and severe drug-related toxicities in patients with nonsquamous non–small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

Proteomic Stratification Test Can Help Guide Second-Line Treatment of NSCLC
A simple serum protein test can help guide treatment decisions between chemotherapy and erlotinib as second-line therapy for patients with non-small-cell lung cancer, according to results of a phase III study presented at ASCO. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Heat Shock Protein 90 Inhibitor Shows Promise in NSCLC
Results from the GALAXY-1 trial showed that the novel second-generation heat shock protein 90 (HSP90) inhibitor ganetespib could potentially improve survival in patients with advanced-stage non–small-cell lung cancer. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Immunotherapy for Advanced Melanoma
Building on the landmark studies of the immunotherapeutic agent ipilimumab just a few years back, ASCO 2013 saw the presentation of truly impressive data on two PD1 blockers, as well as noteworthy studies of other immunotherapeutic approaches to advanced melanoma. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news

ASCO: Fewer Toxicities With Weekly Adjuvant Paclitaxel in Breast Cancer
A phase III trial presented at ASCO showed similar efficacy between two adjuvant paclitaxel regimens, but the weekly regimen led to fewer patient side effects. (Source: Cancer Network)
Source: Cancer Network - June 6, 2013 Category: Cancer & Oncology Source Type: news